Abstract
The Patient Protection and Affordable Care Act (ACA) will greatly increase coverage for treatment of substance use disorders. To realize the benefits of this opportunity, it is critical to develop reliable, valid, and feasible measures of quality to ensure that treatment is accessible and of high quality. The authors review the availability of current quality measures for substance use disorder treatment and conclude there is a pressing need for development, validation, and use of quality measures. They provide recommendations for research and policy changes to increase the likelihood that patients, families, and society benefit from the increased coverage provided by the ACA.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Health Services Accessibility / economics
-
Health Services Accessibility / legislation & jurisprudence*
-
Health Services Needs and Demand / economics
-
Health Services Needs and Demand / legislation & jurisprudence*
-
Humans
-
Insurance Coverage / economics
-
Insurance Coverage / legislation & jurisprudence*
-
Mental Health Services / economics
-
Mental Health Services / legislation & jurisprudence*
-
Patient Protection and Affordable Care Act / economics
-
Patient Protection and Affordable Care Act / legislation & jurisprudence*
-
Substance-Related Disorders / economics
-
Substance-Related Disorders / therapy*
-
United States